Holen Sie sich die Stockscreener-App
71.04
2.00%
-1.45
Schlusskurs vom Vortag:
$72.49
Offen:
$72.62
24-Stunden-Volumen:
196.53K
Relative Volume:
0.45
Marktkapitalisierung:
$1.59B
Einnahmen:
$883.37M
Nettoeinkommen (Verlust:
$71.37M
KGV:
21.20
EPS:
3.3516
Netto-Cashflow:
$150.90M
1W Leistung:
-4.05%
1M Leistung:
-8.17%
6M Leistung:
-27.30%
1J Leistung:
+15.60%
1-Tages-Spanne:
$70.63
$72.90
1-Wochen-Bereich:
$70.63
$77.47
52-Wochen-Spanne:
$56.71
$99.50
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
Firmenname
Ani Pharmaceuticals Inc
Sektor
Telefon
(218) 634-3500
Adresse
210 MAIN STREET WEST, BAUDETTE, MN
Compare ANIP vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANIP
Ani Pharmaceuticals Inc
|
71.03 | 1.62B | 883.37M | 71.37M | 150.90M | 3.3516 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.82 | 56.14B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
114.68 | 48.74B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.05 | 44.85B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
28.78 | 34.12B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
536.19 | 23.35B | 3.13B | 1.27B | 1.12B | 26.39 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-14 | Eingeleitet | Jefferies | Buy |
| 2025-03-12 | Eingeleitet | JP Morgan | Overweight |
| 2024-12-11 | Eingeleitet | Leerink Partners | Outperform |
| 2024-10-11 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-15 | Eingeleitet | CapitalOne | Overweight |
| 2023-08-22 | Bestätigt | H.C. Wainwright | Buy |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2022-09-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-02 | Eingeleitet | Truist | Buy |
| 2020-05-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
| 2019-05-10 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2017-10-16 | Bestätigt | Canaccord Genuity | Buy |
| 2017-07-31 | Eingeleitet | Canaccord Genuity | Buy |
| 2017-02-22 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2016-06-23 | Eingeleitet | Raymond James | Strong Buy |
| 2016-05-24 | Herabstufung | Standpoint Research | Buy → Hold |
| 2015-11-13 | Eingeleitet | Standpoint Research | Buy |
| 2015-09-28 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2015-08-05 | Bestätigt | Oppenheimer | Outperform |
| 2015-08-04 | Bestätigt | ROTH Capital | Neutral |
| 2015-07-31 | Bestätigt | Oppenheimer | Outperform |
| 2015-07-15 | Bestätigt | ROTH Capital | Neutral |
| 2015-06-23 | Bestätigt | Oppenheimer | Outperform |
| 2015-05-18 | Bestätigt | ROTH Capital | Neutral |
| 2015-05-06 | Bestätigt | Oppenheimer | Outperform |
| 2015-04-10 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2015-02-26 | Bestätigt | ROTH Capital | Buy |
| 2015-02-18 | Bestätigt | Oppenheimer | Outperform |
Alle ansehen
Ani Pharmaceuticals Inc Aktie (ANIP) Neueste Nachrichten
Pharma Sector Q1 2026 Earnings Review: Mixed Results & Future OutlookNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
How ANI’s Reaffirmed 2026 Guidance and Rare Disease Push Will Impact ANI Pharmaceuticals (ANIP) Investors - simplywall.st
Beam Therapeutics Stock Surges 23% in 6 Months: What's Driving It? - TradingView
ANI Pharmaceuticals touts rare-disease pivot at Barclays, guides 2026 revenue above $1B - MarketBeat
ANI Pharmaceuticals at Barclays Conference: Rare Disease Focus Drives Growth - Investing.com Canada
Mineralys Stock Rises as FDA Accepts NDA for Hypertension Drug - TradingView
ANI Pharmaceuticals Targets $1.1B 2026 Revenue as Cortrophin Sales Surge, Gout Launch Set for Midyear - Yahoo Finance
Insider Sell: Krista Davis Sells Shares of ANI Pharmaceuticals I - GuruFocus
GSK Out-Licenses Rights for Rare Liver Disease Drug to Alfasigma - Finviz
BMY Advances CELMoD Program With Positive Phase III Results - TradingView
Ani pharmaceuticals head of rare disease sells $30k in stock - Investing.com Nigeria
INCY Wins EC Approval for Label Expansion of Oncology Drug Zynyz - Finviz
Insider Trades And Rare Disease Growth Shape ANI Pharmaceuticals Valuation - Yahoo! Finance Canada
Stephen P Carey At ANI Pharmaceuticals Decides to Exercises Options Worth $86K - Benzinga
Mirum Completes Enrollment & Screening in Liver Disease Studies - TradingView
Generic Pharmaceuticals Q4 Earnings: ANI Pharmaceuticals (NASDAQ:ANIP) Simply the Best - Yahoo Finance
Stephen Carey Sells 7,312 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock - MarketBeat
Immunovant Stock Surges 17% in 3 Months: What's Driving It? - TradingView
AMRN Stock Soars 37.7% in a Year: Here's What You Need to Know - TradingView
Christopher Mutz Sells 417 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock - MarketBeat
Ori Gutwerg Sells 2,060 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock - MarketBeat
ANIP SEC FilingsAni Pharmaceutic 10-K, 10-Q, 8-K Forms - Stock Titan
ESPR to Boost Cardiovascular Portfolio With Corstasis Buyout for $75M - Finviz
Director at ANI Pharmaceuticals (ANIP) sells 6,000 shares - Stock Titan
SVP & CFO At ANI Pharmaceuticals Buys $1.72M of StockANI Pharmaceuticals (NASDAQ:ANIP) - Benzinga
833K Reasons To Be Bullish On ANI Pharmaceuticals StockANI Pharmaceuticals (NASDAQ:ANIP) - Benzinga
SVP Of ANI Pharmaceuticals Makes $1.00M BuyANI Pharmaceuticals (NASDAQ:ANIP) - Benzinga
SVP Of ANI Pharmaceuticals Purchased $464K In StockANI Pharmaceuticals (NASDAQ:ANIP) - Benzinga
ANI Pharmaceuticals (ANIP) Stock Analysis: A Compelling 47% Upside Potential Awaits Investors - DirectorsTalk Interviews
ANI Pharmaceuticals Targets $1B+ Sales in 2026, Pivots to Rare Disease Growth at Raymond James Conf. - MarketBeat
ANI Pharmaceuticals at Raymond James Conference: Rare Disease Focus By Investing.com - Investing.com Canada
ANI Pharmaceuticals Highlights Updated Non-GAAP Metrics to Investors - TipRanks
ANI Pharmaceuticals projects >$1B revenue in 2026, guides $275–$290M adjusted EBITDA - TradingView
ANI Pharmaceuticals (NASDAQ:ANIP) Releases FY 2026 Earnings Guidance - MarketBeat
ANI Pharmaceuticals : Corporate Presentation March 2026 - marketscreener.com
ANI Pharmaceuticals (NASDAQ: ANIP) guides to over $1B in 2026 revenue - Stock Titan
ANI Pharmaceuticals (NASDAQ: ANIP) exec granted 11,116 shares - Stock Titan
ANI Pharmaceuticals (ANIP) SVP receives stock award, withholds shares for taxes - Stock Titan
ANI Pharmaceuticals (ANIP) exec logs stock award and tax share disposal - Stock Titan
ANI Pharmaceuticals (ANIP) CEO logs restricted stock grant and tax-withholding share disposition - Stock Titan
ANI Pharmaceuticals (ANIP) SVP logs stock grant and tax withholding in Form 4 - Stock Titan
ANI Pharmaceuticals (ANIP) SVP reports stock award, tax withholding and LLC-held shares - Stock Titan
ANI Pharmaceuticals (ANIP) HR chief reports stock award and tax withholding - Stock Titan
Restricted stock grant for ANI Pharmaceuticals (ANIP) general counsel - Stock Titan
ANI Pharmaceuticals (ANIP) CFO awarded restricted stock and has shares withheld for taxes - Stock Titan
LLY Wins CHMP Nod for Olumiant's Expanded Use in Alopecia Areata - Finviz
ANI Pharmaceuticals Reshapes Portfolio With Alimera Deal And Rare Disease Push - Yahoo Finance
ANI Pharmaceuticals Q4 2025: Strong Growth, But Execution Risks Emerge (NASDAQ:ANIP) - Seeking Alpha
William Blair Investment Management LLC Sells 141,856 Shares of ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Quantbot Technologies LP Has $4.20 Million Position in ANI Pharmaceuticals, Inc. $ANIP - MarketBeat
Does Record 2025 Profitability and Reaffirmed 2026 Outlook Change The Bull Case For ANI Pharmaceuticals (ANIP)? - simplywall.st
Finanzdaten der Ani Pharmaceuticals Inc-Aktie (ANIP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.81%
1.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):